A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression.

Loebel, Antony; Koblan, Kenneth S; Tsai, Joyce; Deng, Ling; Fava, Maurizio; Kent, Justine; Hopkins, Seth C

Loebel, Antony; Koblan, Kenneth S; Tsai, Joyce; Deng, Ling; Fava, Maurizio; Kent, Justine; Hopkins, Seth C.

Afiliação

Loebel A; Sunovion Pharmaceuticals Inc., Marlborough, MA, United States of America.
Koblan KS; Sunovion Pharmaceuticals Inc., Marlborough, MA, United States of America. Electronic address: kenneth.koblan@sunovion.com.
Tsai J; Sunovion Pharmaceuticals Inc., Marlborough, MA, United States of America.
Deng L; Sunovion Pharmaceuticals Inc., Marlborough, MA, United States of America.
Fava M; Department of Psychiatry, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, United States of America.
Kent J; Sunovion Pharmaceuticals Inc., Marlborough, MA, United States of America.
Hopkins SC; Sunovion Pharmaceuticals Inc., Marlborough, MA, United States of America.

J Affect Disord ; 296: 549-558, 2022 01 01.

Article em En | MEDLINE | ID: mdl-34614447

Assuntos

Transtorno Bipolar; Amissulprida; Transtorno Bipolar/tratamento farmacológico; Depressão; Manual Diagnóstico e Estatístico de Transtornos Mentais; Método Duplo-Cego; Humanos; Resultado do Tratamento

Palavras-chave

Agents, Antidepressive; Amisulpride; Bipolar disorder; Depressive disorder; Enantiomer; Serotonin 7 receptor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtorno Bipolar Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google